A phase-II clinical trial to evaluate the accuracy of FDG [fluorodeoxyglucose]-/FLT [fluoro-L-thymidine]-PET [positron emission tomography] for early prediction of non-progression in patients with advanced NSCLC [non-small cell lung cancer] treated with erlotinib and to associate PET findings with molecular markers
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ERLOPET
- 18 Sep 2009 Planned end date changed from 1 Jan 2009 to 1 Dec 2009as reported by ClinicalTrials.gov.
- 18 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Sep 2009 Biomarkers information updated